Volume 6 Number 11/12 November/December 2005
13 December 2005. Related: Editorial.
2005
7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland
13 December 2005. Related: Conference reports.
Monitoring side effects in resource limited countries
13 December 2005. Related: Conference reports, Side effects.
Uridine supplement reverses thymidine-induced lipoatrophy
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Niacin has beneficial effect on lipids but no reduction in abdominal fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Gluteal implants used to replace lost buttock fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland
13 December 2005. Related: Conference reports.
Pregnancy studies at EACS
13 December 2005. Related: Conference reports, Pregnancy.
Brazil’s deal with Abbott is challenged in courts
13 December 2005. Related: Treatment access.
Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)
13 December 2005. Related: Antiretrovirals.
Tibotec discontinues TMC125 study C227: phase III studies continue
13 December 2005. Related: Antiretrovirals.
New Kaletra tablet formulation (meltrex) approved by FDA
13 December 2005. Related: Antiretrovirals.
GSK closes phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme
13 December 2005. Related: Antiretrovirals.
Schering discontinues phase 2 studies of vicriviroc in treatment naive patients
13 December 2005. Related: Antiretrovirals.
FDA issues approvable letter for Bioject needle-free injection device
13 December 2005. Related: Antiretrovirals.
Cost effectiveness of resistance testing for treatment-naive patients
13 December 2005. Related: Drug resistance.
Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)
13 December 2005. Related: Antiretrovirals, Treatment strategies.
US pregnancy guidelines updated (Dec 2005)
13 December 2005. Related: Pregnancy, Guidelines.
European activists denounce pricing increases for HIV drugs as ‘unbearable’
13 December 2005. Related: Other news.
Guidelines for the use of antiretroviral agents in pediatric HIV infection
13 December 2005. Related: On the web.
American Association For The Study of Liver Diseases (AASLD), November 11-15, 2005 San Francisco
13 December 2005. Related: On the web.
Medscape articles and online papers
13 December 2005. Related: On the web.
Community newsletters and journals
13 December 2005. Related: On the web.
HIV inSite Knowledge Base
13 December 2005. Related: On the web.
Amedeo HIV Medicine
13 December 2005. Related: On the web.
Volume 6 Number 11/12 November/December 2005 PDF
1 December 2005. Related: PDFs.
Volume 6 Number 10 October 2005
13 October 2005. Related: Editorial.
Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005
13 October 2005. Related: Conference reports.
Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference
13 October 2005. Related: Conference reports, Hepatitis coinfection.
Highlights of HIV drug resistance studies presented at the 3rd IAS Conference
13 October 2005. Related: Conference reports, Drug resistance.
GSK stops trials of CCR5 entry inhibitor GW873140 in naive patients
13 October 2005. Related: Antiretrovirals.
AZT comes off patent: generic versions approved for US market
13 October 2005. Related: Antiretrovirals.
Depletion of latent HIV-1 reservoir with valproic acid: interesting data but not a cure
13 October 2005. Related: Treatment access, Cure-related research, Basic science and immunology.
Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy
13 October 2005. Related: Side effects.
Breast milk, HIV suppression and decreased mother to child transmission
13 October 2005. Related: Pregnancy.
Single dose nevirapine infant prophylaxis to reduce mother to child transmission may have similar efficacy to maternal and infant doses
13 October 2005. Related: Pregnancy.
Pharmacokinetics of nevirapine in HIV positive children receiving Thai fixed dose combination
13 October 2005. Related: Paediatric care.
WHO – Patients for patient safety: call for participants
13 October 2005. Related: Other news.
Does buprenorphine have a role in preventing HIV transmission and treating HIV-infected IDUs?
13 October 2005. Related: Other news.
Medscape articles and online papers
13 October 2005. Related: On the web.
Neurological complications of HIV infection
13 October 2005. Related: On the web.
HIV inSite Knowledge Base
13 October 2005. Related: On the web.
WHO list of essential medicines
13 October 2005. Related: On the web.
Volume 6 Number 10 October 2005 PDF
1 October 2005. Related: PDFs.
Volume 6 Number 9 September 2005
14 September 2005. Related: Editorial.
3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil
14 September 2005. Related: Conference reports.
Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy
14 September 2005. Related: Conference reports, HIV prevention and transmission.
Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS
14 September 2005. Related: Conference reports, Pregnancy.
New drugs in pregnancy: atazanavir; T20
14 September 2005. Related: Conference reports, Pregnancy.
Lopinavir/r use in children less than two years old promising results despite low plasma levels
14 September 2005. Related: Conference reports, Paediatric care.
Favourable outcomes in children treated with HAART in the MSF programmes
14 September 2005. Related: Conference reports, Paediatric care.
Encouraging results with cut up generic fixed dose combination tablets in Uganda
14 September 2005. Related: Conference reports, Paediatric care.
Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire
14 September 2005. Related: Conference reports, Paediatric care.
Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results
14 September 2005. Related: Conference reports, Antiretrovirals.
T20 (enfuvirtide) studies presented at Rio
14 September 2005. Related: Conference reports.
Strategies for salvage therapy
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiviral activity of foscarnet in salvage patients
14 September 2005. Related: Conference reports, Antiretrovirals.
Novel strategies with existing drugs
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiretroviral activity of new and novel agents
14 September 2005. Related: Conference reports, Antiretrovirals.
Overview of pharmacology studies
14 September 2005. Related: Conference reports, PK and drug interactions.
Incidence of TB infection despite HAART and treatment in coinfected patients
14 September 2005. Related: Conference reports, TB coinfection.
Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients
14 September 2005. Related: Conference reports, TB coinfection.
Does WHO clinical stage reliably predict who should receive ARV treatment?
14 September 2005. Related: Conference reports, Treatment access.